SynthesisBMC pulmonary medicine2022
Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06929767 (Biomarker Guided Decision-making in Acute Exacerbation of COPD), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarker Guided Decision-making in Acute Exacerbation of COPD: a Feasibility Study
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews.Health technology assessment (Winchester, England) · 2026Pooled it
- Lack of Evidence Regarding Markers Identifying Acute Heart Failure in Patients with COPD: An AI-Supported Systematic Review.International journal of chronic obstructive pulmonary disease · 2024Pooled it
- Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.Respiratory research · 2024Trial
- Article
- Stage-Dependent Reorganization of Inflammatory Biomarker Networks During Acute Exacerbations of COPD.Life (Basel, Switzerland) · 2026Article
- Cardiovascular Risk During the 90-Day Vulnerable Window After COPD Exacerbations: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Beyond pathogens: a narrative review of the immunological nexus of damage-associated molecular patterns and inflammasome activation in sterile AECOPD.Frontiers in immunology · 2026Review
- SPG7-Mediated Regulation of mPTP and Mitochondrial Flickering in COPD: A Bioinformatics-Based Prediction of Mechanistic Framework.International journal of chronic obstructive pulmonary disease · 2026Article
- Explainable Machine Learning Model Based on Routine Admission Laboratory Tests for Predicting New-Onset Hypoalbuminemia in Hospitalized Older Patients with Acute Exacerbation of COPD.Clinical interventions in aging · 2026Article
- Expression and clinical significance of serum C-reactive protein and blood lactate levels in elderly patients with chronic obstructive pulmonary disease complicated by acute lower respiratory tract infection.American journal of translational research · 2026Article
- The effect of indirect moxibustion with the treatment of Ma Ren Pill on patients with acute exacerbation of chronic obstructive pulmonary disease with constipation.Frontiers in medicine · 2026Article
- Association Between Serum Growth Factors and Risk of Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A One-Year Prospective Study.International journal of molecular sciences · 2025Article
- The higher serum uric acid to high-density lipoprotein cholesterol ratio is associated with increased risk of chronic obstructive pulmonary disease: result from NHANES 2011-2018.BMC pulmonary medicine · 2025Article
- The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Artificial neural network risk prediction of COPD exacerbations using urine biomarkers.ERJ open research · 2025Article
- Molecular mechanisms and therapeutic targets of acute exacerbations of chronic obstructive pulmonary disease with Pseudomonas aeruginosa infection.Respiratory research · 2025Article
- Immune cell regulatory networks in chronic obstructive pulmonary disease: mechanistic analysis from innate to adaptive immunity.Frontiers in immunology · 2025Review
- Long-term exposure to ambient air pollutant and acute exacerbations of chronic obstructive pulmonary disease: a retrospective cohort study in Xinjiang, China.Frontiers in public health · 2025Article
- Characteristics of Pathogens of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Hospitalized Patients: A Retrospective Study From 2010 to 2020.Pulmonary medicine · 2025Article
- Prognostic Value of Biomarkers in Chronic Obstructive Pulmonary Disease: A Comprehensive Review.International journal of chronic obstructive pulmonary disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotics are frequently prescribed for acute exacerbations of COPD (AECOPD) even though most do not have a bacterial aetiology. Biomarkers may help clinicians target antibiotic use by identifying AECOPD caused by bacterial pathogens. We aimed to summarise current evidence on the diagnostic accuracy of biomarkers for detecting bacterial versus non-bacterial AECOPD.
methodsWe searched Embase and Medline using a search strategy including terms for COPD, biomarkers and bacterial infection. Data regarding diagnostic accuracy for each biomarker in predicting bacterial cause of exacerbation were extracted and summarised. We used to QUADAS-2 tool to assess risk of bias.
resultsOf 509 papers identified, 39 papers evaluating 61 biomarkers were eligible for inclusion. Moderate quality evidence was found for associations between serum C-reactive protein (CRP), serum procalcitonin (PCT), sputum interleukin (IL)-8 and sputum tumour necrosis factor alpha (TNF-α), and the presence of bacterial pathogens in the sputum of patients with AECOPD. Having bacterial pathogens was associated with a mean difference (higher) CRP and PCT of 29.44 mg/L and 0.76 ng/mL respectively. There was inconsistent or weak evidence for associations between bacterial AECOPD and higher levels of sputum IL-1β, IL-6, myeloperoxidase (MPO) and neutrophil elastase (NE). We did not find any consistent evidence of diagnostic value for other biomarkers.
conclusionsThere is moderate evidence from heterogeneous studies that serum CRP and PCT are of value in differentiating bacterial from non-bacterial AECOPD, and little evidence for other biomarkers. Further high-quality research on the role of biomarkers in identifying bacterial exacerbations is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.